160 related articles for article (PubMed ID: 8757425)
21. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.
Rizzardi GP; Barcellini W; Tambussi G; Lillo F; Malnati M; Perrin L; Lazzarin A
AIDS; 1996 Nov; 10(13):F45-50. PubMed ID: 8931778
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
23. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation.
Zangerle R; Gallati H; Sarcletti M; Weiss G; Denz H; Wachter H; Fuchs D
J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):79-85. PubMed ID: 7903382
[TBL] [Abstract][Full Text] [Related]
24. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
25. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
26. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study.
Stein DS; Lyles RH; Graham NM; Tassoni CJ; Margolick JB; Phair JP; Rinaldo C; Detels R; Saah A; Bilello J
J Infect Dis; 1997 Nov; 176(5):1161-7. PubMed ID: 9359714
[TBL] [Abstract][Full Text] [Related]
27. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II.
Kreuzer KA; Dayer JM; Rockstroh JK; Sauerbruch T; Spengler U
Clin Exp Immunol; 1997 Jul; 109(1):54-8. PubMed ID: 9218824
[TBL] [Abstract][Full Text] [Related]
28. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
Siller L; Martin NL; Kostuchenko P; Beckett L; Rautonen J; Cheng SC; Wara DW
AIDS; 1993 Mar; 7(3):369-73. PubMed ID: 8097095
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.
Fahey JL; Taylor JM; Manna B; Nishanian P; Aziz N; Giorgi JV; Detels R
AIDS; 1998 Sep; 12(13):1581-90. PubMed ID: 9764776
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
33. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.
Zangerle R; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Fuchs D
J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1149-56. PubMed ID: 7932082
[TBL] [Abstract][Full Text] [Related]
34. Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; van der Ende ME; ten Napel CH; Weigel HM; Schreij GS; Kauffmann RH; Koopmans PP; Hoepelman AI; de Boer JB; Weverling GJ
J Infect Dis; 1994 Jun; 169(6):1351-5. PubMed ID: 7910838
[TBL] [Abstract][Full Text] [Related]
35. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
;
AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of membrane-bound tumor necrosis factor-alpha and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load.
Hestdal K; Aukrust P; Müller F; Lien E; Bjerkeli V; Espevik T; Frøland SS
Blood; 1997 Oct; 90(7):2670-9. PubMed ID: 9326234
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
39. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection.
Fuchs D; Krämer A; Reibnegger G; Werner ER; Dierich MP; Goedert JJ; Wachter H
Infection; 1991; 19 Suppl 2():S98-102. PubMed ID: 1673120
[TBL] [Abstract][Full Text] [Related]
40. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
